Missing Information
  • A System Error Has Occured:0177 - Failed to Load All Sections.
Company:  FENNEC PHARMACEUTICALS IN ... (FENC)
Form Type:  4
Filing Date:  6/19/2019 
CIK:  0001211583 
Address:  PO BOX 13628
68 TW ALEXANDER DRIVE
 
City, State, Zip:  RESEARCH TRIANGLE PARK, North Carolina 27709 
Telephone:  (919) 636-4530 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$6.34  
Change: 
0.066 (1.05%)  
Trade Time: 
Dec 06  
Market Cap: 
$126.14M
Trade FENC now with

© 2019  
Description of Business
Fennec Pharmaceuticals Inc. ("Fennec," the "Company," "we," "us," or "our") is a biopharmaceutical company focused on the development of PEDMARKTM (a unique formulation of Sodium Thiosulfate ("STS")) for the prevention of platinum-induced ototoxicity in pediatric cancer patients. We incorporated under the Canada Business Corporations Act ("CBCA") in September 1996. Effective on August 25, 2011, the Company continued from the CBCA to the Business Corporations Act (British Columbia) (the "Continuance"). The Continuance was approved by our shareholders at our June 2011 Annual and Special Meeting and by resolution of the Board of Directors on August 10, 2011. We have four wholly-owned subsidiaries: Oxiquant, Inc. and Fennec Pharmaceuticals, Inc., both Delaware corporations, Cadherin Biomedical Inc., a Canadian company and Fennec Pharmaceuticals (EU) Limited ("Fennec Limited"), an Ireland company formed in 2018.